Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension of the PTI-125-04 Study Evaluating the Safety and Long-Term Treatment of Simufilam in Mild-to-Moderate Alzheimer's Disease Patients

NCT05352763 is registered in ClinicalTrials.gov with Cassava Sciences, Inc. as lead sponsor.

NCT NCT05352763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05352763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension of the PTI-125-04 Study Evaluating the Safety and Long-Term Treatment of Simufilam in Mild-to-Moderate Alzheimer's Disease Patients
Lead sponsor
Cassava Sciences, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
May 12, 2022
Completion date
December 31, 2024
Enrollment
90 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease